Sec. 1. 17-A MRSA §1101, sub-§4-A is enacted to read:

4-A. "Methamphetamine precursor drug" means:

A.__Any drugs or products that contain in the aggregate a quantity of 9 grams or more of ephedrine, pseudoephedrine or phenylpropanolamine or their salts, isomers or salts of isomers, either alone or in combination with other ingredients, in dry or solid nonliquid form; and

B. Any drugs or products that contain in the aggregate a quantity of 9 grams or more of ephedrine, pseudoephedrine or phenylpropanolamine or their salts, isomers or salts of isomers, either alone or in combination with other ingredients, in liquid, liquid-filled capsule or glycerin matrix form if such products are designated as methamphetamine precursor drugs by rule adopted by the Department of Public Safety pursuant to Title 32, section 13795, subsection 5, paragraph A.

Sec. 2. 17-A MRSA §1102, sub-§4, ¶D, as enacted by PL 1987, c. 747, §2, is amended to read:

D. Butyl nitrite or isobutyl nitrite.; and

Sec. 3. 17-A MRSA §1102, sub-§4, ¶E is enacted to read:

E.__A methamphetamine precursor drug.

Sec. 4. 17-A MRSA §1107-A, sub-§3, as enacted by PL 2003, c. 61, §7, is repealed and the following enacted in its place:

3.__It is an affirmative defense to prosecution under this section that:

A.__The substance possessed is industrial hemp; or

B.__That the substance possessed is a methamphetamine precursor drug and was possessed by the defendant for a legitimate medical purpose.

Sec. 5. 22 MRSA c. 556 is enacted to read:

CHAPTER 556

MAINE METH WATCH PROGRAM

§2351. Maine Meth Watch Program